SET8  ||| S:0 E:5 ||| NNP
induces  ||| S:5 E:13 ||| VBZ
epithelial‑mesenchymal  ||| S:13 E:36 ||| CD
transition  ||| S:36 E:47 ||| NN
and  ||| S:47 E:51 ||| CC
enhances  ||| S:51 E:60 ||| VBZ
prostate  ||| S:60 E:69 ||| JJ
cancer  ||| S:69 E:76 ||| NN
cell  ||| S:76 E:81 ||| NN
metastasis  ||| S:81 E:92 ||| NN
by  ||| S:92 E:95 ||| IN
cooperating  ||| S:95 E:107 ||| VBG
with  ||| S:107 E:112 ||| IN
ZEB1  ||| S:112 E:117 ||| NNP
Mounting  ||| S:117 E:126 ||| NNP
evidence  ||| S:126 E:135 ||| NN
suggested  ||| S:135 E:145 ||| VBD
that  ||| S:145 E:150 ||| IN
histone  ||| S:150 E:158 ||| FW
H4K20‑specific  ||| S:158 E:173 ||| FW
methyltransferase  ||| S:173 E:191 ||| FW
SET8  ||| S:191 E:196 ||| FW
is  ||| S:196 E:199 ||| VBZ
required  ||| S:199 E:208 ||| VBN
to  ||| S:208 E:211 ||| TO
maintain  ||| S:211 E:220 ||| VB
the  ||| S:220 E:224 ||| DT
malignant  ||| S:224 E:234 ||| JJ
phenotype  ||| S:234 E:244 ||| NN
of  ||| S:244 E:247 ||| IN
various  ||| S:247 E:255 ||| JJ
cancer  ||| S:255 E:262 ||| NN
types ||| S:262 E:267 ||| NNS
;  ||| S:267 E:269 ||| :
however ||| S:269 E:276 ||| RB
,  ||| S:276 E:278 ||| ,
the  ||| S:278 E:282 ||| DT
role  ||| S:282 E:287 ||| NN
of  ||| S:287 E:290 ||| IN
SET8  ||| S:290 E:295 ||| CD
in  ||| S:295 E:298 ||| IN
mediating  ||| S:298 E:308 ||| JJ
tumor  ||| S:308 E:314 ||| NN
metastasis  ||| S:314 E:325 ||| NN
in  ||| S:325 E:328 ||| IN
prostate  ||| S:328 E:337 ||| JJ
cancer  ||| S:337 E:344 ||| NN
( ||| S:344 E:345 ||| -LRB-
PCa ||| S:345 E:348 ||| NNP
)  ||| S:348 E:350 ||| -RRB-
has  ||| S:350 E:354 ||| VBZ
remained  ||| S:354 E:363 ||| VBN
elusive ||| S:363 E:370 ||| JJ
.  ||| S:370 E:372 ||| .
The  ||| S:372 E:376 ||| DT
present  ||| S:376 E:384 ||| JJ
study  ||| S:384 E:390 ||| NN
demonstrated  ||| S:390 E:403 ||| VBN
that  ||| S:403 E:408 ||| IN
small  ||| S:408 E:414 ||| JJ
interfering  ||| S:414 E:426 ||| NNS
RNA‑mediated  ||| S:426 E:439 ||| VBP
knockdown  ||| S:439 E:449 ||| VBN
of  ||| S:449 E:452 ||| IN
SET8  ||| S:452 E:457 ||| NNP
inhibited  ||| S:457 E:467 ||| VBD
the  ||| S:467 E:471 ||| DT
invasive  ||| S:471 E:480 ||| JJ
potential  ||| S:480 E:490 ||| NN
of  ||| S:490 E:493 ||| IN
the  ||| S:493 E:497 ||| DT
PCa  ||| S:497 E:501 ||| JJ
cell  ||| S:501 E:506 ||| NN
line  ||| S:506 E:511 ||| NN
PC‑3  ||| S:511 E:516 ||| CD
in vitro ||| S:516 E:524 ||| CD
.  ||| S:524 E:526 ||| .
Knockdown  ||| S:526 E:536 ||| NNP
of  ||| S:536 E:539 ||| IN
SET8  ||| S:539 E:544 ||| NNP
reduced  ||| S:544 E:552 ||| VBD
sphere  ||| S:552 E:559 ||| JJ
formation ||| S:559 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
downregulated  ||| S:570 E:584 ||| JJ
E‑cadherin  ||| S:584 E:595 ||| NN
and  ||| S:595 E:599 ||| CC
α‑catenin ||| S:599 E:608 ||| NNP
,  ||| S:608 E:610 ||| ,
and  ||| S:610 E:614 ||| CC
upregulated  ||| S:614 E:626 ||| JJ
N‑cadherin  ||| S:626 E:637 ||| NN
and  ||| S:637 E:641 ||| CC
vimentin  ||| S:641 E:650 ||| JJ
expression  ||| S:650 E:661 ||| NN
in  ||| S:661 E:664 ||| IN
CaP  ||| S:664 E:668 ||| JJ
cells ||| S:668 E:673 ||| NNS
,  ||| S:673 E:675 ||| ,
while  ||| S:675 E:681 ||| IN
upregulation  ||| S:681 E:694 ||| NN
of  ||| S:694 E:697 ||| IN
SET8  ||| S:697 E:702 ||| CD
expression  ||| S:702 E:713 ||| NN
with  ||| S:713 E:718 ||| IN
a  ||| S:718 E:720 ||| DT
recombinant  ||| S:720 E:732 ||| JJ
plasmid  ||| S:732 E:740 ||| NN
had  ||| S:740 E:744 ||| VBD
the  ||| S:744 E:748 ||| DT
opposite  ||| S:748 E:757 ||| JJ
effect ||| S:757 E:763 ||| NN
.  ||| S:763 E:765 ||| .
Furthermore ||| S:765 E:776 ||| RB
,  ||| S:776 E:778 ||| ,
SET8  ||| S:778 E:783 ||| NNP
was  ||| S:783 E:787 ||| VBD
shown  ||| S:787 E:793 ||| VBN
to  ||| S:793 E:796 ||| TO
be  ||| S:796 E:799 ||| VB
physically  ||| S:799 E:810 ||| RB
associated  ||| S:810 E:821 ||| VBN
with  ||| S:821 E:826 ||| IN
the  ||| S:826 E:830 ||| DT
epithelial‑mesenchymal  ||| S:830 E:853 ||| JJ
transition  ||| S:853 E:864 ||| NN
( ||| S:864 E:865 ||| -LRB-
EMT ||| S:865 E:868 ||| NNP
)  ||| S:868 E:870 ||| -RRB-
inducer  ||| S:870 E:878 ||| FW
zinc  ||| S:878 E:883 ||| FW
finger  ||| S:883 E:890 ||| FW
E‑box‑binding  ||| S:890 E:904 ||| FW
homeobox 1  ||| S:904 E:915 ||| FW
( ||| S:915 E:916 ||| -LRB-
ZEB1 ||| S:916 E:920 ||| NNP
)  ||| S:920 E:922 ||| -RRB-
in  ||| S:922 E:925 ||| IN
PCa  ||| S:925 E:929 ||| JJ
cell  ||| S:929 E:934 ||| NN
lines ||| S:934 E:939 ||| NNS
.  ||| S:939 E:941 ||| .
Chromatin  ||| S:941 E:951 ||| NNP
immunoprecipitation  ||| S:951 E:971 ||| VBD
suggested  ||| S:971 E:981 ||| VBN
that  ||| S:981 E:986 ||| IN
SET8  ||| S:986 E:991 ||| CD
binds  ||| S:991 E:997 ||| NN
to  ||| S:997 E:1000 ||| TO
the  ||| S:1000 E:1004 ||| DT
promoter  ||| S:1004 E:1013 ||| NN
of  ||| S:1013 E:1016 ||| IN
cell  ||| S:1016 E:1021 ||| NN
adhesion  ||| S:1021 E:1030 ||| NN
molecule  ||| S:1030 E:1039 ||| NN
E‑cadherin  ||| S:1039 E:1050 ||| NN
and  ||| S:1050 E:1054 ||| CC
vimentin ||| S:1054 E:1062 ||| NN
.  ||| S:1062 E:1064 ||| .
Luciferase  ||| S:1064 E:1075 ||| JJ
reporter  ||| S:1075 E:1084 ||| NN
assays  ||| S:1084 E:1091 ||| VBZ
suggested  ||| S:1091 E:1101 ||| VBN
that  ||| S:1101 E:1106 ||| IN
E‑cadherin  ||| S:1106 E:1117 ||| NNP
and  ||| S:1117 E:1121 ||| CC
vimentin  ||| S:1121 E:1130 ||| NNS
are  ||| S:1130 E:1134 ||| VBP
direct  ||| S:1134 E:1141 ||| JJ
targets  ||| S:1141 E:1149 ||| NNS
of  ||| S:1149 E:1152 ||| IN
SET8 ||| S:1152 E:1156 ||| CD
;  ||| S:1156 E:1158 ||| :
furthermore ||| S:1158 E:1169 ||| RB
,  ||| S:1169 E:1171 ||| ,
loss‑  ||| S:1171 E:1177 ||| NNP
and  ||| S:1177 E:1181 ||| CC
gain‑of  ||| S:1181 E:1189 ||| CD
function  ||| S:1189 E:1198 ||| NN
studies  ||| S:1198 E:1206 ||| NNS
of  ||| S:1206 E:1209 ||| IN
SET8  ||| S:1209 E:1214 ||| NNP
and  ||| S:1214 E:1218 ||| CC
ZEB1  ||| S:1218 E:1223 ||| NNP
indicated  ||| S:1223 E:1233 ||| VBD
that  ||| S:1233 E:1238 ||| DT
suppression  ||| S:1238 E:1250 ||| NN
of  ||| S:1250 E:1253 ||| IN
downstream  ||| S:1253 E:1264 ||| JJ
E‑cadherin  ||| S:1264 E:1275 ||| NN
and  ||| S:1275 E:1279 ||| CC
activation  ||| S:1279 E:1290 ||| NN
of  ||| S:1290 E:1293 ||| IN
vimentin  ||| S:1293 E:1302 ||| NNS
are  ||| S:1302 E:1306 ||| VBP
important  ||| S:1306 E:1316 ||| JJ
mechanisms  ||| S:1316 E:1327 ||| NNS
by  ||| S:1327 E:1330 ||| IN
which  ||| S:1330 E:1336 ||| WDT
SET8  ||| S:1336 E:1341 ||| NNP
and  ||| S:1341 E:1345 ||| CC
ZEB1  ||| S:1345 E:1350 ||| FW
cooperatively  ||| S:1350 E:1364 ||| FW
trigger  ||| S:1364 E:1372 ||| FW
metastasis ||| S:1372 E:1382 ||| FW
.  ||| S:1382 E:1384 ||| .
Furthermore ||| S:1384 E:1395 ||| RB
,  ||| S:1395 E:1397 ||| ,
SET8‑induced  ||| S:1397 E:1410 ||| FW
methylated  ||| S:1410 E:1421 ||| FW
H4K20  ||| S:1421 E:1427 ||| NNP
was  ||| S:1427 E:1431 ||| VBD
indicated  ||| S:1431 E:1441 ||| VBN
to  ||| S:1441 E:1444 ||| TO
exert  ||| S:1444 E:1450 ||| VB
a  ||| S:1450 E:1452 ||| DT
dual  ||| S:1452 E:1457 ||| JJ
function  ||| S:1457 E:1466 ||| NN
in  ||| S:1466 E:1469 ||| IN
ZEB1‑regulated  ||| S:1469 E:1484 ||| CD
gene  ||| S:1484 E:1489 ||| NN
expression ||| S:1489 E:1499 ||| NN
.  ||| S:1499 E:1501 ||| .
In  ||| S:1501 E:1504 ||| IN
conclusion ||| S:1504 E:1514 ||| NN
,  ||| S:1514 E:1516 ||| ,
the  ||| S:1516 E:1520 ||| DT
present  ||| S:1520 E:1528 ||| JJ
study  ||| S:1528 E:1534 ||| NN
revealed  ||| S:1534 E:1543 ||| VBD
that  ||| S:1543 E:1548 ||| IN
SET8  ||| S:1548 E:1553 ||| NNP
and  ||| S:1553 E:1557 ||| CC
ZEB1  ||| S:1557 E:1562 ||| NNP
are  ||| S:1562 E:1566 ||| VBP
functionally  ||| S:1566 E:1579 ||| JJ
interdependent  ||| S:1579 E:1594 ||| NN
in  ||| S:1594 E:1597 ||| IN
promoting  ||| S:1597 E:1607 ||| VBG
the  ||| S:1607 E:1611 ||| DT
EMT  ||| S:1611 E:1615 ||| NNP
and  ||| S:1615 E:1619 ||| CC
enhancing  ||| S:1619 E:1629 ||| VBG
the  ||| S:1629 E:1633 ||| DT
invasive  ||| S:1633 E:1642 ||| JJ
potential  ||| S:1642 E:1652 ||| NN
of  ||| S:1652 E:1655 ||| IN
PCa  ||| S:1655 E:1659 ||| JJ
cells  ||| S:1659 E:1665 ||| NNS
in vitro ||| S:1665 E:1673 ||| VBP
.  ||| S:1673 E:1675 ||| .
